The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item interview-based clinical assessment that evaluates cognitive deficits and the degree to which these deficits impair patients’ day-to-day functioning. It was originally developed in 2001 at Duke University Medical Center by VeraSci CEO and Co-Founder Dr. Richard Keefe and is licensed through VeraSci. The SCoRS is used in registration-level clinical trials, academic research and in clinical settings. The SCoRS contains questions about the patient’s ability to manage cognitively demanding, functionally relevant, everyday tasks.
The SCoRS items were developed to assess the following cognitive domains:• Attention
- Working Memory
- Language Production
- Problem Solving
- Motor Skills
- Social Cognition
A recently published manuscript: Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS) by Philip D. Harvey, Anzalee Khan, Alexandra Atkins, Trina M. Walker, Richard S.E. Keefe is a review of research utilizing the SCoRS that outlines the development, evaluation, validation, and implementation of the SCoRS to assess whether the scale meets the criteria as a functional co-primary measure as defined by the MATRICS-CT initiative.
The MATRICS-CT initiative was developed by the NIMH in conjunction with industry and FDA partners to offer a systematic translation (T) of the MATRICS consensus cognitive assessment battery (MCCB) and to develop a co-primary (C) measure of outcomes for clinical trials. This publication addresses the appropriateness of the SCoRS as a co-primary measure and its global applicability.
Interview-based co-primary assessments should be: 1) practical and easy to administer for a clinician or researcher; 2) validated in individuals with schizophrenia; 3) contain the relevant areas of cognition and functioning applicable to schizophrenia; 4) able to assess all phases and severity levels of schizophrenia; 5) capable of monitoring disease progression; 6) minimal burden to patients; and 7) sensitive to assess treatment effects. A review of the literature was conducted to present information on the development, psychometric properties and usage of the SCoRS. Review of the development of the SCoRS followed the parameters outlined for scale development on content expert validation and feedback.
The SCoRS shows good psychometric properties in various studies and demonstrates low burden on clinicians and patients. The items measure global concepts that do not require notable cultural modification, making international use feasible. While multiple performance-based tests in cognition and functional outcomes are available, there is a need for a multi-domain, interview-based assessment of cognitive progression and treatment response in clinical trials. The SCoRS appears to meet many of the criteria for an optimal co-primary measure for schizophrenia cognition clinical trials as defined in the MATRICS-CT initiative.
To read the full publication in Schizophrenia Research: Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS) by Philip D. Harvey, Anzalee Khan, Alexandra Atkins*, Trina M. Walker*, Richard S.E. Keefe* CLICK HERE
Note: * VeraSci Leadership